The long-term goal of this project is to define the role of bioactive sphingolipid metabolizing enzymes in inflammation and to target these enzymes for novel anti- inflammatory therapy. The PI's laboratory has an established track record of expertise in sphingolipid metabolism and function. Studies from the previous funding period have led us into a novel exciting direction on the role and regulation of bioactive sphingolipid metabolizing enzymes in inflammation with strong possibilities for therapeutic development. Ceramidase and Sphingosine Kinase (SK) are two very critical enzymes in sphingolipid metabolism as they are implicated in the regulation of bioactive sphingolipid levels. Ceramidases breakdown ceramide to generate sphingosine, which is then phosphorylated by SK to yield sphingosine-1-phosphate (S1P). S1P, a highly bioactive sphingolipid, is produced in many inflammatory cells and acts both extracellularly and intracellularly on recently defined targets. S1P mediates/modulates several important biologic activities including inflammatory responses. Recently we have begun to uncover a specific role for acid ceramidase (AC) in inflammation in cells and in mouse models of inflammation. In addition, we have chemically synthesized several AC inhibitors and begun testing them for biologic activity. Our laboratory also pioneered studies on the role of SK1 in inflammation and we have specifically demonstrated a key role for SK1/S1P in regulating the induction of the cyclooxygenase (COX-2)/prostaglandin pathway in vitro and in mouse models of colitis and arthritis. In addition we have synthesized specific SK1 inhibitors and tested them for biologic activity. Importantly, our studies are leading us to appreciate complexities in vivo whereby altering the AC/SK1/S1P pathway in immune cells versus epithelial cells may differentially regulate inflammatory responses in mice. Moreover, our data show that SK1 has cardiovascular-sparing effects when compared with COX inhibitors. These data, therefore, lead us to propose the hypothesis that the AC/SK1/S1P pathway is a fundamental pathway in inflammatory diseases and that targeting the pathway may result in novel disease-modifying therapy in inflammation. This hypothesis will be addressed by the following Specific Aims: 1. Establish and define the role of AC in mouse models of inflammation. 2. Establish and define the role of SK1 in mouse models of inflammation. 3. Develop pharmacologic inhibition of AC and SK1 as novel inflammatory therapeutic targets. These compelling studies will not only implicate the pathway of AC/SK1/S1P at the center of the inflammatory process but will also begin to reveal clear and highly relevant differences over the COX-2 pathway that could lead to ground breaking novel anti-inflammatory therapy.

Public Health Relevance

The VA patient population has a high incidence of chronic inflammatory conditions, in particular, arthritis and colitis. These conditions are difficult to treat and generally are not sensitive to mny available modalities of treatment. Moreover, chronic inflammatory conditions are increasingly thought to lead to cancer. Tumor necrosis factor (TNF) and COX-2 are implicated in most of these chronic inflammatory conditions and recent highly effective anti-inflammatory therapy is geared at blocking their action. However, these anti-inflammatory agents have proven to have cardiovascular and other side effects. Our preliminary studies demonstrate that sphingolipid molecules are intermediates in the action of TNF on COX-2. We will therefore utilize models of rheumatoid arthritis and inflammatory colitis to study the roles of the sphingolipid regulating enzymes acid ceramidase and sphingosine kinase in these models of inflammation and target these enzymes for novel therapies in the treatment of chronic inflammation.

National Institute of Health (NIH)
Veterans Affairs (VA)
Non-HHS Research Projects (I01)
Project #
Application #
Study Section
Cellular and Molecular Medicine (CAMM)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northport VA Medical Center
United States
Zip Code
Newcomb, Benjamin; Rhein, Cosima; Mileva, Izolda et al. (2018) Identification of an acid sphingomyelinase ceramide kinase pathway in the regulation of the chemokine CCL5. J Lipid Res 59:1219-1229
Espaillat, Mel Pilar; Snider, Ashley J; Qiu, Zhijuan et al. (2018) Loss of acid ceramidase in myeloid cells suppresses intestinal neutrophil recruitment. FASEB J 32:2339-2353
Schwartz, Nicholas U; Linzer, Ryan W; Truman, Jean-Philip et al. (2018) Decreased ceramide underlies mitochondrial dysfunction in Charcot-Marie-Tooth 2F. FASEB J 32:1716-1728
Coant, Nicolas; García-Barros, Mónica; Zhang, Qifeng et al. (2018) AKT as a key target for growth promoting functions of neutral ceramidase in colon cancer cells. Oncogene 37:3852-3863
Snider, Justin M; Snider, Ashley J; Obeid, Lina M et al. (2018) Probing de novo sphingolipid metabolism in mammalian cells utilizing mass spectrometry. J Lipid Res 59:1046-1057
Pulkoski-Gross, Michael J; Uys, Joachim D; Orr-Gandy, K Alexa et al. (2017) Novel sphingosine kinase-1 inhibitor, LCL351, reduces immune responses in murine DSS-induced colitis. Prostaglandins Other Lipid Mediat 130:47-56
Espaillat, Mel Pilar; Kew, Richard R; Obeid, Lina M (2017) Sphingolipids in neutrophil function and inflammatory responses: Mechanisms and implications for intestinal immunity and inflammation in ulcerative colitis. Adv Biol Regul 63:140-155
Dupre, Tess V; Doll, Mark A; Shah, Parag P et al. (2017) Inhibiting glucosylceramide synthase exacerbates cisplatin-induced acute kidney injury. J Lipid Res 58:1439-1452
Senkal, Can E; Salama, Mohamed F; Snider, Ashley J et al. (2017) Ceramide Is Metabolized to Acylceramide and Stored in Lipid Droplets. Cell Metab 25:686-697
Snider, Ashley J; Bialkowska, Agnieszka B; Ghaleb, Amr M et al. (2016) Murine Model for Colitis-Associated Cancer of the Colon. Methods Mol Biol 1438:245-54

Showing the most recent 10 out of 45 publications